Myeloproliferative neoplasms
Explore this paper's citation graph
- Type
- article
- Published
- 2025-04-01
- Cited by
- 0
- References
- 9
- OpenAlex
- https://openalex.org/W4210298848
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:265996286
Keywords
Polycythaemia, Medicine, Myelofibrosis, Polycythemia vera, Thrombosis
References
- The myeloproliferative disorders.
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
- Genetic basis and molecular profiling in myeloproliferative neoplasms
- Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies
- Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine
- Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations
Cited by
No citing papers recorded for this paper.
Related papers
- Hydroxycarbamide associated platelet count oscillations in a patient with polycythaemia vera. A case report and review of the literature
- Essential thrombocythaemia: a phenotypic spectrum with polycythaemia vera – a case report
- Anagrelide
- 32P in the treatment of myeloproliferative disorders
- Hydroxyurea and periodicity in myeloproliferative disease
- Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide
- Management of polycythaemia vera: a critical review of current data
- Myeloproliferative disorders
- Myeloproliferative neoplasms